Eligibility for treatment with omalizumab in Italy and Germany

R. Buhl, G. W. Canonica, A. Gili Marco, C. Ruland (Mainz, Germany; Genoa, Italy; Basel, Switzerland)

Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Session: Allergen immunotherapy and anti-immunoglobulin E
Session type: Poster Discussion
Number: 277
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Buhl, G. W. Canonica, A. Gili Marco, C. Ruland (Mainz, Germany; Genoa, Italy; Basel, Switzerland). Eligibility for treatment with omalizumab in Italy and Germany. Eur Respir J 2011; 38: Suppl. 55, 277

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and tolerability of linezolid in the treatment of MDR-TB cases: a TBNET study in Germany and Italy
Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Year: 2008


Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK
Source: Eur Respir J, 55 (6) 1902363; 10.1183/13993003.02363-2019
Year: 2020



Clinical outcome in patients treated with omalizumab during pre-approval period in France
Source: Eur Respir J 2007; 30: Suppl. 51, 621s
Year: 2007

Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL study
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016


Guidelines improved asthma treatment in Gunma, Japan
Source: Eur Respir J 2003; 22: Suppl. 45, 258s
Year: 2003

Real-world treatment of incident COPD patients in Germany
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021


Prescription of antitussives in asthma: A cross-sectional study in primary care in France and in Italy
Source: Annual Congress 2012 - Epidemiology of various respiratory diseases
Year: 2012

Cost-effectiveness of budesonide/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden
Source: Annual Congress 2010 - Does cost-effectiveness go together with best quality of treatment? New drivers in medicine
Year: 2010

Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017



Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019



Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

Evaluation of COPD treatment success by office-based pneumologists in Germany using the example of tiotropium
Source: Annual Congress 2011 - Quality of life and respiratory symptom management in primary care
Year: 2011

Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany
Source: Eur Respir J 2015; 46: 1826-1829
Year: 2015


The current treatment of asthma in Italy
Source: Eur Respir J 2002; 20: Suppl. 38, 427s
Year: 2002

The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Drug therapy of childhood asthma: results of a community-based survey in Germany
Source: Eur Respir J 2001; 18: Suppl. 33, 121s
Year: 2001

Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Targeted literature review: epidemiology of severe and uncontrolled asthma and associated biomarkers in France, Germany, Italy, Spain and the UK
Source: Virtual Congress 2020 – Clinical parameters in severe asthma
Year: 2020


Long-term follow-up of patients under omalizumab initiated during the pre-approval period in France
Source: Annual Congress 2010 - Management of airway disease
Year: 2010


Cost-of-illness of COPD in Germany
Source: Eur Respir J 2003; 22: Suppl. 45, 376s
Year: 2003